Treatment of nonalcoholic fatty liver disease: The role of medical, surgical, and endoscopic weight loss

Journal of Clinical and Translational Hepatology

Volumn 3, Issue 3, 2015, Pages 230-238

  Popov, Violeta B ^a   Lim, Joseph K ^b  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Bariatric surgery; Endoscopic therapy; Exercise; Fatty liver; Nonalcoholic steatohepatitis; Pharmacotherapy; Weight loss

Indexed keywords

EID: 84969997322     PISSN: 22250719     EISSN: 23108819     Source Type: Journal    
DOI: 10.14218/JCTH.2015.00019     Document Type: Review

References (82)

1. Angulo P. Nonalcoholic fatty liver disease. Rev Gastroenterol Mex 2005;70: 52–56.
2. Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, Cohen JC, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004;40:1387–1395. doi: 10. 1002/hep.20466.
3. Bedogni G, Miglioli L, Masutti F, Castiglione A, Crocè LS, Tiribelli C, et al. Incidence and natural course of fatty liver in the general population: the Dionysos study. Hepatology 2007;46:1387–1391. doi: 10.1002/hep.21827.
4. Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther 2011;34:274–285. doi: 10.1111/j.1365-2036.2011.04724.x.
5. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999;116:1413–1419.
6. Adams LA, Lymp JF, St Sauver J, Sanderson SO, Lindor KD, Feldstein A, et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005;129:113–121. doi: 10.1053/j.gastro. 2005.04.014.
7. Bugianesi E, Leone N, Vanni E, Marchesini G, Brunello F, Carucci P, et al. Expanding the natural history of nonalcoholic steatohepatitis: from crypto-genic cirrhosis to hepatocellular carcinoma. Gastroenterology 2002;123: 134–140. doi: 10.1053/gast.2002.34168.
8. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012;55:2005–2023. doi: 10.1002/hep.25762.
9. Argo CK, Caldwell SH. Epidemiology and natural history of non-alcoholic steatohepatitis. Clin Liver Dis 2009;13:511–531. doi: 10.1016/j.cld.2009. 07.005.
10. Clark JM, Brancati FL, Diehl AM. The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol 2003;98: 960–967. doi: 10.1111/j.1572-0241.2003.07486.x.
11. Ruhl CE, Everhart JE. Determinants of the association of overweight with elevated serum alanine aminotransferase activity in the United States. Gas-troenterology 2003;124:71–79. doi: 10.1053/gast.2003.50004.
12. Mofrad P, Contos MJ, Haque M, Sargeant C, Fisher RA, Luketic VA, et al. Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology 2003;37:1286–1292. doi: 10.1053/jhep.2003.50229.
13. Kahl S, Straßburger K, Nowotny B, Livingstone R, Klüppelholz B, Keßel K, et al. Comparison of liver fat indices for the diagnosis of hepatic steatosis and insulin resistance. PLoS One 2014;9:e94059. doi: 10.1371/journal.pone. 0094059.
14. Bedogni G, Bellentani S, Miglioli L, Masutti F, Passalacqua M, Castiglione A, et al. The Fatty Liver Index: a simple and accurate predictor of hepatic stea-tosis in the general population. BMC Gastroenterol 2006;6:33. doi: 10.1186/1471-230X-6-33.
15. Nascimbeni F, Pais R, Bellentani S, Day CP, Ratziu V, Loria P, et al. From NAFLD in clinical practice to answers from guidelines. J Hepatol 2013;59: 859–871. doi: 10.1016/j.jhep.2013.05.044.
16. Ratziu V, Charlotte F, Heurtier A, Gombert S, Giral P, Bruckert E, et al. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastro-enterology 2005;128:1898–1906. doi: 10.1053/j.gastro.2005.03.084.
17. Rinella ME. Nonalcoholic fatty liver disease: a systematic review. JAMA 2015; 313:2263–2273. doi: 10.1001/jama.2015.5370.
18. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005;41:1313–1321. doi: 10.1002/hep. 20701.
19. Musso G, Gambino R, Cassader M, Pagano G. Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann Med 2011;43:617–649. doi: 10.3109/07853890.2010.518623.
20. Machado MV, Cortez-Pinto H. Non-invasive diagnosis of non-alcoholic fatty liver disease. A critical appraisal. J Hepatol 2013;58:1007–1019. doi: 10.1016/j.jhep.2012.11.021.
21. Kim HJ, Lee KE, Kim DJ, Kim SK, Ahn CW, Lim SK, et al. Metabolic significance of nonalcoholic fatty liver disease in nonobese, nondiabetic adults. Arch Intern Med 2004;164:2169–2175. doi: 10.1001/archinte.164.19.2169.
22. Bugianesi E, Gastaldelli A, Vanni E, Gambino R, Cassader M, Baldi S, et al. Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: sites and mechanisms. Diabetologia 2005;48:634–642. doi: 10. 1007/s00125-005-1682-x.
23. Donnelly KL, Smith CI, Schwarzenberg SJ, Jessurun J, Boldt MD, Parks EJ. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest 2005;115:1343–1351. doi: 10.1172/JCI200523621.
24. Cusi K. Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications. Gastroenterology 2012;142:711–725, e6. doi: 10.1053/j.gastro.2012.02.003.
25. Uyeda K, Repa JJ. Carbohydrate response element binding protein, ChREBP, a transcription factor coupling hepatic glucose utilization and lipid synthesis. Cell Metab 2006;4:107–110. doi: 10.1016/j.cmet.2006.06.008.
26. Jornayvaz FR, Shulman GI. Diacylglycerol activation of protein kinase Cepsilon and hepatic insulin resistance. Cell Metab 2012;15:574–584. doi: 10.1016/j.cmet.2012.03.005.
27. Day CP, James OF. Steatohepatitis: a tale of two “hits”? Gastroenterology 1998;114:842–845.
28. Tilg H, Moschen AR. Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology 2010;52: 1836–1846. doi: 10.1002/hep.24001.
29. Argo CK, Northup PG, Al-Osaimi AM, Caldwell SH. Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis. J Hepatol 2009;51:371–379. doi: 10.1016/j.jhep.2009.03.019.
30. Teli MR, James OF, Burt AD, Bennett MK, Day CP. The natural history of nonalcoholic fatty liver: a follow-up study. Hepatology 1995;22:1714–1719.
31. Söderberg C, Stål P, Askling J, Glaumann H, Lindberg G, Marmur J, et al. Decreased survival of subjects with elevated liver function tests during a 28-year follow-up. Hepatology 2010;51:595–602. doi: 10.1002/hep.23314.
32. Haring R, Wallaschofski H, Nauck M, Dörr M, Baumeister SE, Völzke H. Ultra-sonographic hepatic steatosis increases prediction of mortality risk from elevated serum gamma-glutamyl transpeptidase levels. Hepatology 2009;50: 1403–1411. doi: 10.1002/hep.23135.
33. Yamada T, Fukatsu M, Suzuki S, Wada T, Yoshida T, Joh T. Fatty liver predicts impaired fasting glucose and type 2 diabetes mellitus in Japanese undergoing a health checkup. J Gastroenterol Hepatol 2010;25:352–356. doi: 10.1111/j.1440-1746.2009.05998.x.
34. Fraser A, Harris R, Sattar N, Ebrahim S, Davey Smith G, Lawlor DA. Alanine aminotransferase, gamma-glutamyltransferase, and incident diabetes: the British Women’s Heart and Health Study and meta-analysis. Diabetes Care 2009;32:741–750. doi: 10.2337/dc08-1870.
35. Targher G, Zoppini G, Day CP. Risk of all-cause and cardiovascular mortality in patients with chronic liver disease. Gut 2011;60:1602–1603; author reply 1603–1604. doi: 10.1136/gut.2010.230656.
36. Baffy G, Brunt EM, Caldwell SH. Hepatocellular carcinoma in non-alcoholic fatty liver disease: an emerging menace. J Hepatol 2012;56:1384–1391. doi: 10.1016/j.jhep.2011.10.027.
37. Capristo E, Miele L, Forgione A, Vero V, Farnetti S, Mingrone G, et al. Nutritional aspects in patients with non-alcoholic steatohepatitis (NASH). Eur Rev Med Pharmacol Sci 2005;9:265–268.
38. Palmer M, Schaffner F. Effect of weight reduction on hepatic abnormalities in overweight patients. Gastroenterology 1990;99:1408–1413.
39. Ueno T, Sugawara H, Sujaku K, Hashimoto O, Tsuji R, Tamaki S, et al. Therapeutic effects of restricted diet and exercise in obese patients with fatty liver. J Hepatol 1997;27:103–107. doi: 10.1016/S0168-8278(97)80287-5.
40. Lewis MC, Phillips ML, Slavotinek JP, Kow L, Thompson CH, Toouli J. Change in liver size and fat content after treatment with Optifast very low calorie diet. Obes Surg 2006;16:697–701. doi: 10.1381/096089206777346682.
41. Shah K, Stufflebam A, Hilton TN, Sinacore DR, Klein S, Villareal DT. Diet and exercise interventions reduce intrahepatic fat content and improve insulin sensitivity in obese older adults. Obesity (Silver Spring) 2009;17:2162– 2168. doi: 10.1038/oby.2009.126.
42. Lazo M, Solga SF, Horska A, Bonekamp S, Diehl AM, Brancati FL, et al. Effect of a 12-month intensive lifestyle intervention on hepatic steatosis in adults with type 2 diabetes. Diabetes Care 2010;33:2156–2163. doi: 10.2337/dc10-0856.
43. Bell LN, Wang J, Muralidharan S, Chalasani S, Fullenkamp AM, Wilson LA, et al. Relationship between adipose tissue insulin resistance and liver histology in nonalcoholic steatohepatitis: a pioglitazone versus vitamin E versus placebo for the treatment of nondiabetic patients with nonalcoholic steatohepatitis trial follow-up study. Hepatology 2012;56:1311–1318. doi: 10.1002/hep.25805.
44. Wong VW, Chan RS, Wong GL, Cheung BH, Chu WC, Yeung DK, et al. Community-based lifestyle modification programme for non-alcoholic fatty liver disease: a randomized controlled trial. J Hepatol 2013;59:536–542. doi: 10.1016/j.jhep.2013.04.013.
45. Thoma C, Day CP, Trenell MI. Lifestyle interventions for the treatment of nonalcoholic fatty liver disease in adults: a systematic review. J Hepatol 2012; 56:255–266. doi: 10.1016/j.jhep.2011.06.010.
46. Asrih M, Jornayvaz FR. Diets and nonalcoholic fatty liver disease: the good and the bad. Clin Nutr 2014. 33:186–190. doi: 10.1016/j.clnu.2013.11.003.
47. Barrera F, George J. The role of diet and nutritional intervention for the management of patients with NAFLD. Clin Liver Dis 2014;18:91–112. doi: 10.1016/j.cld.2013.09.009.
48. Sacks FM, Bray GA, Carey VJ, Smith SR, Ryan DH, Anton SD, et al. Comparison of weight-loss diets with different compositions of fat, protein, and carbohydrates. N Engl J Med 2009;360:859–873. doi: 10.1056/NEJMoa0804748.
49. Pérez-Guisado J, Muñoz-Serrano A. The effect of the Spanish Ketogenic Mediterranean Diet on nonalcoholic fatty liver disease: a pilot study. J Med Food 2011;14:677–680. doi: 10.1089/jmf.2011.0075.
50. Promrat K, Kleiner DE, Niemeier HM, Jackvony E, Kearns M, Wands JR, et al. Weight loss with a low-carbohydrate, Mediterranean, or low-fat diet. N Engl J Med 2008;359:229–241. doi: 10.1056/NEJMoa0708681.
51. Promrat K, Kleiner DE, Niemeier HM, Jackvony E, Kearns M, Wands JR, et al. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology 2010;51:121–129. doi: 10.1002/hep.23276.
52. Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, Torres-Gonzalez A, Gra-Oramas B, Gonzalez-Fabian L, et al. Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis. Gastroenterology 2015; Apr 10. doi: 10.1053/j.gastro.2015.04.005.
53. Diabets prevention program research group, Knowler WC, Fowler SE, Hamman RF, Christophi CA, Hoffman HJ, et al. Diabetes Prevention Program Research Group. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet 2009;374: 677–686. doi: 10.1016/S0140-6736(09)61457-4.
54. Williamson DA, Anton SD, Han H, Champagne CM, Allen R, LeBlanc E, et al. Adherence is a multi-dimensional construct in the POUNDS LOST trial. J Behav Med 2010;33:35–46. doi: 10.1007/s10865-009-9230-7.
55. Burra P, Germani G. Orthotopic liver transplantation in non-alcoholic fatty liver disease patients. Rev Recent Clin Trials 2014;9:210–216. doi: 10. 2174/1574887109666141216105224.
56. Angelico F, Burattin M, Alessandri C, Del Ben M, Lirussi F. Drugs improving insulin resistance for non-alcoholic fatty liver disease and/or non-alcoholic steatohepatitis. Cochrane Database Syst Rev 2007;1:CD005166. doi: 10. 1002/14651858.CD005166.pub2.
57. Sofer E, Boaz M, Matas Z, Mashavi M, Shargorodsky M. Treatment with insulin sensitizer metformin improves arterial properties, metabolic parameters, and liver function in patients with nonalcoholic fatty liver disease: a random-ized, placebo-controlled trial. Metabolism 2011;60:1278–1284. doi: 10. 1016/j.metabol.2011.01.011.
58. Harrison SA, Fecht W, Brunt EM, Neuschwander-Tetri BA. Orlistat for overweight subjects with nonalcoholic steatohepatitis: A randomized, prospective trial. Hepatology 2009;49:80–86. doi: 10.1002/hep.22575.
59. Zein CO, Yerian LM, Gogate P, Lopez R, Kirwan JP, Feldstein AE, et al. Pentox-ifylline improves nonalcoholic steatohepatitis: a randomized placebo-controlled trial. Hepatology 2011;54:1610–1619. doi: 10.1002/hep.24544.
60. Armstrong MJ. Liraglutide is effective in the histological clearance of nonalcoholic steatohepatitis in a multicentre, double-blinded, randomised, placebo-controlled phase II trial. In: International Liver Congress, Vienna, Austria, 2015.
61. Armstrong MJ, Barton D, Gaunt P, Hull D, Guo K, Stocken D, et al. Liraglutide efficacy and action in non-alcoholic steatohepatitis (LEAN): study protocol for a phase II multicentre, double-blinded, randomised, controlled trial. BMJ Open 2013;3:e003995. doi: 10.1136/bmjopen-2013-003995.
62. Peng L, Wang J, Li F. Weight reduction for non-alcoholic fatty liver disease. Cochrane Database Syst Rev 2011:CD003619. doi: 10.1002/14651858. CD003619.pub3.
63. Shalhub S, Parsee A, Gallagher SF, Haines KL, Willkomm C, Brantley SG, et al. The importance of routine liver biopsy in diagnosing nonalcoholic stea-tohepatitis in bariatric patients. Obes Surg 2004;14:54–59. doi: 10.1381/096089204772787293
64. Kleiner DE, Berk PD, Hsu JY, Courcoulas AP, Flum D, Khandelwal S, et al. Hepatic pathology among patients without known liver disease undergoing bariatric surgery: observations and a perspective from the longitudinal assessment of bariatric surgery (LABS) study. Semin Liver Dis 2014;34: 98–107. doi: 10.1055/s-0034-1371083.
65. Hafeez S, Ahmed MH. Bariatric surgery as potential treatment for nonalcoholic fatty liver disease: a future treatment by choice or by chance? J Obes 2013;2013:839275. doi: 10.1155/2013/839275.
66. Rabl C, Campos GM. The impact of bariatric surgery on nonalcoholic steato-hepatitis. Semin Liver Dis 2012;32:80–91. doi: 10.1055/s-0032-1306428.
67. Chavez-Tapia NC, Tellez-Avila FI, Barrientos-Gutierrez T, Mendez-Sanchez N, Lizardi-Cervera J, Uribe M, et al. Bariatric surgery for non-alcoholic steato-hepatitis in obese patients. Cochrane Database Syst Rev 2010:CD007340. doi: 10.1002/14651858.CD007340.pub2.
68. Taitano AA, Markow M, Finan JE, Wheeler DE, Gonzalvo JP, Murr MM. Bariatric surgery improves histological features of nonalcoholic Fatty liver disease and liver fibrosis. J Gastrointest Surg 2015;19:429–437. doi: 10.1007/s11605-014-2678-y.
69. Cazzo E, Jimenez LS, Pareja JC, Chaim EA. Effect of Roux-en-y Gastric Bypass on Nonalcoholic Fatty Liver Disease Evaluated Through NAFLD Fibrosis Score: a Prospective Study. Obes Surg 2015;25:982–985. doi: 10.1007/s11695-014-1489-2.
70. Dixon JB, Bhathal PS, Hughes NR, O’Brien PE. Nonalcoholic fatty liver disease: Improvement in liver histological analysis with weight loss. Hepa-tology 2004;39:1647–1654. doi: 10.1002/hep.20251.
71. Karcz WK, Krawczykowski D, Kuesters S, Marjanovic G, Kulemann B, Grobe H, et al. Influence of Sleeve Gastrectomy on NASH and Type 2 Diabetes Mellitus. J Obes 2011;2011:765473. doi: 10.1155/2011/765473.
72. Kral JG, Thung SN, Biron S, Hould FS, Lebel S, Marceau S, et al. Effects of surgical treatment of the metabolic syndrome on liver fibrosis and cirrhosis. Surgery 2004;135:48–58. doi: 10.1016/j.surg.2003.10.003.
73. Keshishian A, Zahriya K, Willes EB. Duodenal switch has no detrimental effects on hepatic function and improves hepatic steatohepatitis after 6 months. Obes Surg 2005;15:1418–1423. doi: 10.1381/096089205774859290.
74. Mathurin P, Hollebecque A, Arnalsteen L, Buob D, Leteurtre E, Caiazzo R, et al. Prospective study of the long-term effects of bariatric surgery on liver injury in patients without advanced disease. Gastroenterology 2009;137: 532–540. doi: 10.1053/j.gastro.2009.04.052.
75. Ekstedt M, Franzén LE, Mathiesen UL, Thorelius L, Holmqvist M, Bodemar G, et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006;44:865–873. doi: 10.1002/hep.21327.
76. Adams LA, Sanderson S, Lindor KD, Angulo P. The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. J Hepatol 2005;42:132–138. doi: 10.1016/j.jhep.2004. 09.012.
77. Burza MA, Romeo S, Kotronen A, Svensson PA, Sjöholm K, Torgerson JS, et al. Long-term effect of bariatric surgery on liver enzymes in the Swedish Obese Subjects (SOS) study. PLoS One 2013;8:e60495. doi: 10.1371/journal.pone.0060495.
78. Ryou M, Ryan MB, Thompson CC. Current status of endoluminal bariatric procedures for primary and revision indications. Gastrointest Endosc Clin N Am 2011;21:315–333. doi: 10.1016/j.giec.2011.02.004.
79. Popov V, Kumar N, Thompson CC. Intragastric balloon as a treatment for nonalcoholic fatty liver disease in adults: a systematic review and meta-anal-ysis. In: Obesity Week, Boston, Massachusetts, USA, November 2014.
80. Lee YM, Low HC, Lim LG, Dan YY, Aung MO, Cheng CL, et al. Intragastric balloon significantly improves nonalcoholic fatty liver disease activity score in obese patients with nonalcoholic steatohepatitis: a pilot study. Gastroint-est Endosc 2012;76:756–760. doi: 10.1016/j.gie.2012.05.023.
81. Imaz I, Martínez-Cervell C, García-Alvarez EE, Sendra-Gutiérrez JM, González-Enríquez J. Safety and effectiveness of the intragastric balloon for obesity. A meta-analysis. Obes Surg 2008;18:841–846. doi: 10.1007/s11695-007-9331-8.
82. de Jonge C, Rensen SS, Koek GH, Joosten MF, Buurman WA, Bouvy ND, et al. Endoscopic duodenal-jejunal bypass liner rapidly improves plasma parameters of nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2013;11: 1517–1520. doi: 10.1016/j.cgh.2013.07.029.